Role of chemotherapy in clinical T2N0M0 gastric cancer.
Univariate analysis
DOI:
10.1200/jco.2023.41.4_suppl.308
Publication Date:
2023-01-24T21:05:07Z
AUTHORS (4)
ABSTRACT
308 Background: The role of chemotherapy for patients with early stage, node-negative gastric adenocarcinoma (T2N0M0) remains unclear. Possible options are surgery alone, followed by adjuvant chemotherapy, or perioperative chemotherapy. objective our study was to investigate the and sequence in T2N0M0 adenocarcinoma. Methods: National Cancer Data Base (2006-2017) used identify Patients were categorized into 3 groups, alone (S), (AC), peri-operative (POC). Univariate multivariable Cox proportional-hazards models performed evaluate treatment differences overall survival (OS). further sub-categorized two subgroups based on number regional nodes examined, less than 15 (RNE<15) greater equal (RNE>15). each subgroup assess within groups. Results: retrospective analyzed 3,142 between 2006 2017. Surgery represented 2,090 (66.5%), AC group had 360 (11.5%), POC 692 (22.0%). median age population 70 yrs. Mean inpatient stay 12.5 days S, 9.2 10.1 (p<0.001). In model, (HR 0.75, p=0.003), RNE>15 0.73, p<0.001), treated at academic facilities 0.84, p=0.005), female sex p=0.004), Asian race 0.69, p=0.002) better outcomes. There 1,526 (49.2%) RNE<15 1,577 (50.8%) RNE>15. Subgroup analysis showed that beneficial 0.74, p= 0.029). an improved 0.72, 0.017) model. Conclusions: found be having a Gastric Cancer. However, lymph examined during influences this association. Perioperative maybe who under staged due inadequate exploration surgery.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....